Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 36,626 | 35,021 | 32,496 | 42,327 | 64,717 |
| Marketable Securities | 67,913 | 78,103 | 84,197 | 83,080 | 79,852 |
| TOTAL | $107,716 | $116,404 | $119,480 | $127,196 | $146,072 |
| Non-Current Assets | |||||
| Investments And Advances | 0 | 0 | 8,806 | 10,059 | 0 |
| Other Non-Current Assets | 39 | 78 | 115 | 152 | 100 |
| TOTAL | $39 | $78 | $8,921 | $10,211 | $100 |
| Total Assets | $107,755 | $116,482 | $128,401 | $137,407 | $146,172 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,303 | 1,309 | 4,243 | 1,921 | 3,223 |
| Accrued Expenses | 2,955 | 3,714 | 4,788 | 5,174 | 3,918 |
| TOTAL | $5,297 | $5,101 | $9,146 | $7,247 | $7,180 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $5,297 | $5,101 | $9,146 | $7,247 | $7,180 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 61,752 | 32,585 | 32,522 | 32,522 | 32,195 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | -356,999 | -346,349 | -336,781 | -323,873 | -313,487 |
| Other shareholders' equity | 8 | 120 | 117 | 76 | 121 |
| TOTAL | $102,458 | $111,381 | $119,255 | $130,160 | $138,992 |
| Total Liabilities And Equity | $107,755 | $116,482 | $128,401 | $137,407 | $146,172 |